Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31, which drives itch and is involved in inflammation and skin barrier ...

Roflumilast demonstrated effectiveness and safety in treating psoriasis, with added benefits for patients with comorbidities.

A consistent safety profile and sustained efficacy were observed in patients with moderate to severe plaque psoriasis.

Feeling a little itchy? Here's how to recognize the most commonly undiagnosed skin irritations, including the one you may ...

Individuals on immunosuppressants should discontinue them prior to patch testing, if at all possible, to avoid tarnishing the test results, according to updated guidelines from the North American ...

Cold weather, dry air, an overactive immune system or our modern lifestyle. The causes may vary, but an increasing number of ...

More than 125 million people worldwide suffer from some form of psoriasis. If you’ve struggled with your skin health this ...

Stress has a huge impact on the way our skin ages. Stress hormones speed up the ageing process, causing more fine lines and wrinkles.

Is it simply heat rash, or could it be a more persistent skin condition like eczema? Learn how to spot the difference.